SCHEMBL19205328

SCHEMBL19205328

Oc1ccccc1C1(C(F)(F)F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 14/20 0.46
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
CA12 O43570 1/20 0.38
GMNN O75496 1/20 0.38
ALDH1A1 P00352 1/20 0.38
EGFR P00533 1/20 0.38
CA2 P00918 1/20 0.38
LMNA P02545 1/20 0.38
FYN P06241 1/20 0.38
POLB P06746 1/20 0.38
CA3 P07451 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
MMP9 P14780 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
CA4 P22748 1/20 0.38
APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20455827 0.77 PDK2 (0.43) PDK2CA2CA5AHDAC4
SCHEMBL21543242 0.77 PDK2 (0.44) PDK2LMNAHDAC4
SCHEMBL21543374 0.77 PDK2 (0.43) PDK2ALDH1A1CYP3A4MAPTALOX15
SCHEMBL28100618 0.77 PDK2 (0.43) PDK2TDP1L3MBTL1HDAC4
SCHEMBL28236004 0.75 ALDH1A1 (0.45) PDK2KDM4ECA12ALDH1A1CA2
SCHEMBL22443382 0.74 PDK2 (0.51) PDK2KDM4ENPC1ALDH1A1MAPT
SCHEMBL24653826 0.72 PDK2 (0.41) PDK2KDM4ENPC1CA12GMNN
SCHEMBL19291084 0.72 PDK2 (0.47) PDK2LMNAMAPTMEN1KMT2A
SCHEMBL16767609 0.72 PDK2 (0.35) PDK2
SCHEMBL24654099 0.72 PDK2 (0.41) PDK2KDM4ENPC1CA12GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210971-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-10-16 EP disclosed
EP-3210971-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-10-16 EP disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 US disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 US disclosed
US-9944596-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-04-17 US disclosed
EP-3210971-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-08-30 EP disclosed
EP-3210971-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-08-30 EP disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 US disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 US disclosed
US-20170233339-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233339-A1 HETEROCYCLIC COMPOUND RBP4, RBP1, RARA PDK2 3111/4885KDM4E 2536/4885NPC1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.